Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -0.84% | -8.88% | +96.67% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The stock, which is currently worth 2024 to 0.35 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+96.67% | 247M | C | ||
+38.59% | 727B | C+ | ||
-7.89% | 347B | C+ | ||
+15.66% | 319B | B- | ||
+0.24% | 274B | C+ | ||
+13.21% | 238B | B+ | ||
+7.09% | 204B | B- | ||
-6.09% | 203B | A+ | ||
+4.23% | 161B | C+ | ||
-1.70% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EBS Stock
- Ratings Emergent BioSolutions Inc.